| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Franz-Volhard-Clinic, Max-Delbrück-Center for Molecular Medicine, University Hospital Charité, Humboldt-University of Berlin, 13125 Berlin, Germany
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones that are involved in water and electrolyte homeostasis in heart failure. Although both hormones exert almost identical biological actions, the differential regulation of cardiac ANP and BNP mRNA in compensated and overt heart failure is not known. To study the hypothesis that cardiac BNP is more specifically induced in overt heart failure, a large aortocaval shunt of 30 days duration was produced in rats and compared with compensated heart failure. Compensated heart failure was induced either by a small shunt of 30 days duration or by a large shunt of 3 days duration. Both heart failure models were characterized by increased cardiac weight, which was significantly higher in the large-shunt model, and central venous pressure. Left ventricular end-diastolic pressure was elevated only in the overt heart failure group (control: 5.7 ± 0.7; small shunt: 8.6 ± 0.9; large shunt 3 days: 8.5 ± 1.7; large shunt 30 days: 15.9 ± 2.6 mmHg; P < 0.01). ANP and BNP plasma concentrations were elevated in both heart failure models. In compensated heart failure, ANP mRNA expression was induced in both ventricles. In contrast, ventricular BNP mRNA expression was not upregulated in any of the compensated heart failure models, whereas it increased in overt heart failure (left ventricle: 359 ± 104% of control, P < 0.001; right ventricle: 237 ± 33%, P < 0.01). A similar pattern of mRNA regulation was observed in the atria. These data indicate that, in contrast to ANP, cardiac BNP mRNA expression might be induced specifically in overt heart failure, pointing toward the possible role of BNP as a marker of the transition from compensated to overt heart failure.
atrial natriuretic peptide; brain natriuretic peptide; gene expression; aortocaval shunt
This article has been cited by other articles:
|
|
 |
|
  G. Tripepi, F. Mattace-Raso, F. Mallamaci, F. A. Benedetto, J. Witteman, L. Malatino, and C. Zoccali Biomarkers of Left Atrial Volume: A Longitudinal Study in Patients With End Stage Renal Disease Hypertension, October 1, 2009; 54(4): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toischer, H. Kogler, G. Tenderich, C. Grebe, T. Seidler, P. N. Van, K. Jung, R. Knoll, R. Korfer, and G. Hasenfuss Elevated Afterload, Neuroendocrine Stimulation, and Human Heart Failure Increase BNP Levels and Inhibit Preload-Dependent SERCA Upregulation Circ Heart Fail, November 1, 2008; 1(4): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Kerr, O. C. Raffel, G. A. Whalley, I. Zeng, and R. A. Stewart Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation Eur. Heart J., February 1, 2008; 29(3): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Murray, J. D. Gardner, S. P. Levick, G. L. Brower, L. G. Morgan, and J. S. Janicki Response of cardiac mast cells to atrial natriuretic peptide Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1216 - H1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Bingham, L. Ooi, L. Kozera, E. White, and I. C. Wood The Repressor Element 1-Silencing Transcription Factor Regulates Heart-Specific Gene Expression Using Multiple Chromatin-Modifying Complexes Mol. Cell. Biol., June 1, 2007; 27(11): 4082 - 4092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Yue, T. Arai, M. Terashima, A. Y. Sheikh, F. Cao, D. Charo, G. Hoyt, R. C. Robbins, E. A. Ashley, J. Wu, et al. Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2106 - H2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, Y. Tatara, A. Shiota, S. Sugano, S. Takeda, et al. Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin II Hypertension, April 1, 2006; 47(4): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Agnoletti, A. Cargnoni, L. Agnoletti, M. Di Marcello, P. Balzarini, E. Pasini, G. Gitti, P. Martina, R. Ardesi, and R. Ferrari Experimental Ischemic Cardiomyopathy: Insights into Remodeling, Physiological Adaptation, and Humoral Response Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vanderheyden, M. Goethals, S. Verstreken, B. De Bruyne, K. Muller, E. Van Schuerbeeck, and J. Bartunek Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Langenickel, I. Pagel, J. Buttgereit, K. Tenner, M. Lindner, R. Dietz, R. Willenbrock, and M. Bader Rat corin gene: molecular cloning and reduced expression in experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1516 - H1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Magnusson, O. Melander, B. Israelsson, A. Grubb, L. Groop, and S. Jovinge Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease Diabetes Care, August 1, 2004; 27(8): 1929 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vanderheyden, J. Bartunek, and M. Goethals Brain and other natriuretic peptides: molecular aspects Eur J Heart Fail, March 15, 2004; 6(3): 261 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Torrado, E. Lopez, A. Centeno, A. Castro-Beiras, and A. T. Mikhailov Left-right asymmetric ventricular expression of CARP in the piglet heart: regional response to experimental heart failure Eur J Heart Fail, March 1, 2004; 6(2): 161 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Christoffersen, J. P. Goetze, E. D. Bartels, M. O. Larsen, U. Ribel, J. F. Rehfeld, B. Rolin, and L. B. Nielsen Chamber-Dependent Expression of Brain Natriuretic Peptide and Its mRNA in Normal and Diabetic Pig Heart Hypertension, July 1, 2002; 40(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Bialik, Z. A. Abassi, I. Hammel, J. Winaver, and D. Lewinson Evaluation of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Atrial Granules of Rats with Experimental Congestive Heart Failure J. Histochem. Cytochem., October 1, 2001; 49(10): 1293 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C Kone Molecular biology of natriuretic peptides and nitric oxide synthases Cardiovasc Res, August 15, 2001; 51(3): 429 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenbrock, S. Philipp, V. Mitrovic, and R. Dietz Neurohumoral blockade in CHF management Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1_suppl): 24 - 30. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
